Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...

In 2019, esketamine (Spravato), derived from ketamine, was approved by the FDA as a nasal spray for treatment-resistant depression. While ketamine therapy has shown promising results, its use ...

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.